Flot.bio x Philip Hemme

Flot.bio
  • 0.0 (0)
  • LIFE SCIENCES
  • UPDATED MONTHLY

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

  1. Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56

    APR 13

    Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56

    Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences investments in Europe via the Life Sciences VC Coalition. We chat about building European biotech champions like Argenx, the thriving Chinese biotech space, and why life should be fun, not only dealflow. --- This episode is brought to you by GeneNovate Investors Day, an invite-only event for scientists, startups, investors, and industry leaders working at the forefront of cell and gene therapies. Learn more: https://bit.ly/flot-genenovate or reach out to [nadja.pahl@bih-charite.de](mailto:nadja.pahl@bih-charite.de) --- ⭐️ ABOUT THE SPEAKER Sander co-founded Forbion in 2006. Prior to co-founding Forbion, Sander co-founded ABN AMRO Capital/Life Sciences in 2000. Sander serves on the boards of NorthSea Therapeutics and Azafaros, with previous board roles at NewAmsterdam Pharma, Replimune and uniQure. 🔗 LINKS MENTIONED Forbion website — https://forbion.com/Forbion Joins Newly Launched European Life Sciences Coalition — https://forbion.com/news-insights/news/forbion-joins-newly-launched-european-life-sciences-coalition/Novartis acquires Gyroscope Therapeutics — https://www.novartis.com/news/media-releases/novartis-acquire-gyroscope-therapeutics-adding-one-time-gene-therapy-could-transform-care-geographic-atrophy-leading-cause-blindnessGSK acquires Aiolos Bio — https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-aiolos-bio/European Biotech Act — https://health.ec.europa.eu/publications/proposal-regulation-establish-measures-strengthen-unions-biotechnology-and-biomanufacturing-sectors_enCapital markets union — https://finance.ec.europa.eu/financial-markets/financial-markets-policy/capital-markets-union_enGimv discontinues activities for new Life Sciences investments — https://www.gimv.com/en/news/gimv-increases-focus-strategic-objectives-and-discontinues-activities-new-life-sciencesWhy the Strait of Hormuz matters so much in the Iran war — https://www.bbc.co.uk/news/articles/c78n6p09pznoAntoine Papiernik, Sofinnova | Billion Investing with Balance — https://flot.bio/episode/antoine-papiernik-sofinnova-ebillion-biotech-investing-with-balance/Christina Takke, V-Bio Ventures 🇧🇪 | Wonder VC Woman | E17 — https://flot.bio/episode/christina-takke-v-bio-ventures/Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 — https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/sander-slootweg-forbion-eu-biotech-investment/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:13] Uniting European biotech VCs[00:09:25] Why European pension funds overlook biotech VCs[00:17:36] Making European biotech an attractive market[00:30:24] Forbion’s “special sauce” and company culture[00:39:31] Sourcing China’s biotech assets from Europe[00:49:51] European biotech robustness in energy crises[00:52:19] Learning science as an investor[00:57:18] Sander Slootweg on skis[01:00:55] Quick-fire questions

    1h 7m
  2. Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]

    APR 8

    Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]

    Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines. We discuss how Immunethep could challenge Pfizer’s $7bn+ Prevnar, and how one pharma company got on board after a representative said he doesn’t believe in vaccines! --- For transparency, this episode has been sponsored by Immunethep. Learn more at https://bit.ly/flot-immunethep --- ⭐️ ABOUT THE SPEAKERS Bruno is Immunethep’s co-founder and CEO, and co-founder of the startup creator Venture Catalysts. He also co-founded the tech startup Abyssal, which was acquired by marine robotics company Ocean Infinity in 2021. Co-founder and CSO Pedro is a biomedical scientist previously serving as an Assistant Researcher at i3S. He has a PhD in Biomedical Sciences from the University of Porto and boasts over 30 peer-reviewed publications. 🔗 LINKS MENTIONED Immunethep website — https://www.immunethep.com/When Cancer is no longer the biggest threat: AMR’s growing shadow over oncology — https://www.incate.net/when-cancer-is-no-longer-the-biggest-threat-amrs-growing-shadow-over-oncology/Antimicrobial resistance WHO page — https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistanceCenter for Global Development: The Economics of Antibiotic Resistance — https://www.cgdev.org/sites/default/files/economics-antibiotic-resistance.pdfGSK completes Affinivax acquisition — https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/António Portela, BIAL 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54 —https://flot.bio/episode/antonio-portela-bial-parkinsons-biopharma/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/immunethep-antimicrobial-resistance/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:10] The overlooked antimicrobial resistance crisis[00:10:26] Immunethep: When Bruno Santos and Pedro Madureira teamed up[00:15:41] Taking down multiple superbugs with a single vaccine[00:27:30] Preparing to challenge Pfizer’s $7bn+ Prevnar[00:42:11] The Portuguese biotech ecosystem[00:46:10] Bruno Santos’ cross-disciplinary experience[00:48:09] Not taking ‘no’ for an answer from big pharma[00:51:44] Immunethep’s IP and tech transfer achievements [00:55:44] Quick-fire questions

    1h 3m
  3. António Portela, Bial 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54

    MAR 30

    António Portela, Bial 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54

    We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned. We cover Bial’s pipeline, including treatments for epilepsy and Parkinson’s, and why Bial’s multigenerational leadership story is nowhere as dramatic as HBO’s “Succession.” ---Avance is where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance.--- ⭐️ ABOUT THE SPEAKER Prior to leading Bial, António worked at Roche in the UK as a Medical Sales Representative and a Market Analyst. While he worked at Roche, he also launched a Hepatitis C drug.António holds a degree in Economics from the Faculty of Economics at the University of Porto and an Executive MBA from the Porto Business School. 🔗 LINKS MENTIONED Bial’s website — https://www.bial.com/enBial 2024 financials — https://downloads.ctfassets.net/oyx9uzi3vj2y/XTmSUhXd7ggVEnpJLx0Ch/7a22a851246d910c517e064fca4b6968/Consolidated_Management_Report_BIAL_Holding_2024.pdfBial launches KYNMOBI in Portugal and Spain — https://bial.com/en/media/news/bial-launches-kynmobi-in-portugal-and-spainSuccession TV show — https://www.imdb.com/title/tt7660850/BIO-Europe Spring — https://informaconnect.com/bioeurope-spring/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/António-Portela-BIAL-parkinsons-biopharma/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:31] Bial’s humble beginnings[00:05:59] Behind the scenes of the Portela family[00:12:45] A CNS innovator pipeline[00:18:42] From small molecules to biologics[00:21:17] Sourcing Portuguese talent from overseas[00:24:14] Manufacturing critical for gene therapy[00:26:21] António Portela’s dynamic leadership[00:27:38] Quick-fire questions

    31 min
  4. Claus Crone Fuglsang, Novonesis 🇩🇰 | Biosolutions, Industrial biotech, Synbio | E53

    FEB 17

    Claus Crone Fuglsang, Novonesis 🇩🇰 | Biosolutions, Industrial biotech, Synbio | E53

    Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up. ⭐️ ABOUT THE SPEAKER Claus first joined Novozymes in 1993 and led its R&D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA. 🔗 LINKS MENTIONED Novonesis’ website — https://www.novonesis.com/enMerger of Novozymes and Chr Hansen — https://www.novonesis.com/en/news/novozymes-and-chr-hansen-announce-name-future-combined-company-novonesisNovonesis’ nine-month results in 2025 — https://backend.novonesis.com/sites/default/files/document/2025-11/2025_46_9M_Interim_report.pdfNovonesis and Benchling partnership in 2024 — https://www.benchling.com/news/novonesis-and-benchling-long-term-partnership-to-power-rdEU biosolutions — https://research-and-innovation.ec.europa.eu/research-area/environment/bioeconomy/bio-based-products-and-processes_en 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/claus-crone-fuglsang-novonesis-biosolutions/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:19] Novonesis: the Novozymes and Chr Hansen merger[00:09:51] Under the consumer radar[00:12:52] Business divisions and myriad applications[00:20:46] The scaling challenge in biosolutions[00:27:39] Novonesis’ profitability and growth[00:36:34] Genetic engineering and cool patents[00:47:57] Novonesis’ growing AI use[00:56:34] Claus Crone Fuglsang’s enthusiasm for his work[01:00:09] Industrial biotech globally[01:04:15] Quick-fire questions

    1h 11m
  5. Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored]

    FEB 9

    Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored]

    At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: https://bit.ly/cereno-e52--- ⭐️ ABOUT THE SPEAKER Sten joined Cereno as CEO in 2015, with decades of experience in pharma, ranging from Monsanto Pharma to AstraZeneca. 🔗 LINKS MENTIONED Cereno’s website - https://cerenoscientific.com/Cereno Scientific | BioStock Life Science Summit 2024 - [https://www.youtu.be/A5b3Ud_PSas](https://www.youtube.com/watch?v=A5b3Ud_PSas)Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension **-** https://cerenoscientific.com/press-single/?releaseIdentifier=2D7F159764FDB891Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial **-** https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trialCereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) - https://cerenoscientific.com/press-single/?releaseIdentifier=008944355F62DA91Competing drug Winrevair / sotatercept by US Merck - https://www.drugs.com/winrevair.html 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/sten-sorensen-cereno-drug-repurposing/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:04] Cereno's Phase2A results[00:21:59] Phase2B[00:32:41] Cereno's pipeline[00:40:56] The finances of running a Phase2B[00:45:07] Investor base of Cereno[00:50:42] A strong team is crucial for Cereno[00:55:41] The Swedish biotech ecosystem[01:02:54] Sten Sörensen's background[01:10:39] Success in drug repurposing[01:16:03] Quickfire

    1h 25m
  6. Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis, Long-Acting Injections | E51

    FEB 2

    Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis, Long-Acting Injections | E51

    Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breathe new life into generic drugs, making it easier for patients to stick to their treatment regimen. This has applications in many diseases, including hormonal disorders and obesity, with new formulations of GLP-1 agonists.He also discusses how long-acting versions of buprenorphine can help patients to overcome opioid addiction and tackle the global opioid crisis. --- Learn how YSDS helps move your most sensitive life sciences shipments worldwide, safely, on time, with full visibility at https://bit.ly/ysds-flotbio. --- ⭐️ ABOUT THE SPEAKER Fredrik joined Camurus in 2002 as a member of the board and CEO in 2003. Before this, he was CEO of Heptahelix AB and a leading academic at Lund University and the University of Oxford. 🔗 LINKS MENTIONED Camurus’ website - https://www.camurus.com/Oczyesa’s approval - https://www.camurus.com/media/press-releases/2025/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu/Brixadi’s approval - https://braeburnrx.com/media/press-releases/braeburns-brixadi-buprenorphine-extended-release-subcutaneous-injection-ciii-receives-fda-approval-for-moderate-to-severe-opioid-use-disorderEmpire of Pain: The Secret History of the Sackler Dynasty - https://www.amazon.com/Empire-Pain-History-Sackler-Dynasty/dp/0385545681Camurus regains worldwide development and commercialization rights to CAM2029 from Novartis - https://www.camurus.com/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/Camurus and Lilly enter collaboration and license agreement - https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/Nitazenes: Super-strength opioids spreading across Europe and North America - UN - https://www.bbc.com/news/articles/crgge1ez0r2o 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:47] Camurus: the $4-billion powerhouse[00:08:25] The FluidCrystal technology[00:15:24] Buvidal tackles opioid addiction[00:26:05] Oczyesa’s commercial challenges[00:31:03] Metabolic programmes in progress[00:34:45] 4 years of profits[00:37:00] Solving the opioid crisis[00:46:44] Europe’s long-acting drugs scene[00:51:05] Fredrik Tiberg’s background[00:55:15] Quick-fire questions

    1h 1m
  7. Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50

    JAN 12

    Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50

    Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China. --- Learn more about Transgene: https://bit.ly/tg_flotbio --- ⭐️ ABOUT THE SPEAKER Alessandro became Transgene’s CEO in 2023 after joining in 2022 as Chairman of the Board of Directors. He also played a key role in Gilead Sciences’ acquisition of Kite Pharma and the regulatory approval of the CAR-T therapy Yescarta. 🔗 LINKS MENTIONED Transgene’s website - https://www.transgene.fr/Transgene’s €105 million fundraising - https://www.globenewswire.com/news-release/2025/11/26/3195422/0/en/Transgene-Successfully-Completes-a-Fundraising-of-c-105-Million.htmlFDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neckGilead Sciences’ acquisition of Kite Pharma for $11.9 billion - https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billionJohnson & Johnson’s collaboration and license deal withLegend Biotech - https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-chinese-company-legend-biotech-to-develop-investigational-car-t-anti-cancer-therapy 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/alessandro-riva-transgene-cancer-vaccines/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:02] Transgene, the French biotech heavyweight[00:04:55] Standout personalized cancer vaccine[00:25:33] Transgene’s €105 million fundraising [00:32:05] Catalysts and oncolytic viruses

    1h 6m
  8. Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

    JAN 6

    Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

    Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting. The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy. We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems. ----------------------------------------------------------------------- Get expert legal advisory support for growing your biotech from Osborne Clarke at https://bit.ly/oc-flotbio ---------------------------------------------------------------------- ⭐️ ABOUT THE SPEAKER With many years of experience in big pharma, Pascal had top-level positions at Novartis Oncology. He later served as CEO, and most recently Chairman, of Atara Biotherapeutics. Alongside his Jeito role, he sits on the boards of companies including Ipsen, Medincell, Catalym, Xylocor and CDR-Life. 🔗 LINKS MENTIONED Jeito’s website: https://www.jeito.life/en/home/Stefano Portolano, Azafaros | Rare Diseases, Small Molecules Revival | E40: https://www.youtube.com/watch?v=gdaPW7xg_qkOtello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/pascal-touchon-jeito/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:40] The rise of Kymriah and Ebvallo[00:05:40] CAR-T: crazy innovations and valuations[00:20:35] Solid tumor challenges[00:23:18] Cell therapy manufacturing and in vivo CAR-T[00:31:38] Catching the innovation wave at Jeito Capital[00:39:29] VC models and European biotech gems[00:52:51] Biotech without borders[01:05:49] France’s rising pharma stars [01:08:30] Quick-fire questions

    1h 15m
See All (56)

About

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

Information

  • Creator
    Flot.bio
  • Years Active
    2023 - 2026
  • Episodes
    56
  • Rating
    Clean
  • Copyright
    © Flot.bio
  • Show Website
    Flot.bio x Philip Hemme

You Might Also Like